Skip to main content
SpringerLink
Log in

Prognostic value of serum soluble Fas in patients with locally advanced unresectable rectal cancer receiving concurrent chemoradiotherapy

  • Published:
Journal of Zhejiang University SCIENCE B Aims and scope Submit manuscript

Abstract

Objective

This study was designed to detect the changes of serum soluble Fas (sFas) levels in patients with locally advanced unresectable rectal cancer (LAURC), and to explore its prognostic value of response.

Methods

Soluble samples were obtained from LAURC subjects, treated by concurrent chemoradiotherapy, before treatment and one month after treatment. Healthy donor serum samples were used as controls. sFas concentration was measured by enzyme-linked immunosorbent assay (ELISA).

Results

The sFas levels before treatment and one month after treatment were both significantly higher in LAURC subjects than in healthy controls [(8.79±1.39) and (7.74±1.32) vs. (5.53±1.13) ng/L, P<0.01]. The sFas levels before treatment and one month after treatment were significantly lower in the response group (complete and partial responses) than in the non-response group (stable and progressive diseases) [(8.50±1.25) vs. (10.17±1.26) ng/L, P<0.01 and (7.50±1.24) vs. (8.90±1.13) ng/L, P<0.01, respectively]. The one-year survival rate was 54.2% and 82.6% in those with sFas levels >8.79 ng/L and <8.79 ng/L before treatment (P<0.02), respectively, 50.0% and 87.0% in those with sFas levels >7.74 ng/L and <7.74 ng/L one month after treatment (P<0.01), respectively.

Conclusions

The sFas level is higher in LAURC subjects than in healthy controls. Concurrent chemoradiotherapy can reduce sFas levels in LAURC patients. The monitoring of sFas may provide prognostic information for LAURC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Abbasova, S.G., Vysotskii, M.M., Ovchinnikova, L.K., Obusheva, M.N., Digaeva, M.A., Britvin, T.A., Bahoeva, K.A., Karabekova, Z.K., Kazantzeva, I.A., Mamedov, U.R., et al., 2009. Cancer and soluble Fas. Bull. Exp. Biol. Med., 148(4):638–642. [doi:10.1007/s10517-010-0784-8]

    Article  CAS  PubMed  Google Scholar 

  • Bewick, M., Conlon, M., Parissenti, A.M., Lee, H., Zhang, L., Glück, S., Lafrenie, R.M., 2001. Soluble Fas (CD95) is a prognostic factor in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous stem cell transplantation. J. Hematother. Stem. Cell. Res., 10(6):759–768. [doi:10.1089/152581601317210854]

    Article  CAS  PubMed  Google Scholar 

  • Boroumand-Noughabi, S., Sima, H.R., Ghaffarzadehgan, K., Jafarzadeh, M., Raziee, H.R., Hosseinnezhad, H., Moaven, O., Rajabi-Mashhadi, M.T., Azarian, A.A., Mashhadinejad, M., et al., 2010. Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma. BMC Cancer, 10(1):275. [doi:10.1186/1471-2407-10-275]

    Article  PubMed  CAS  Google Scholar 

  • Bosset, J.F., Calais, G., Daban, A., Berger, C., Radosevic-Jelic, L., Maingon, P., Bardet, E., Pierart, M., Briffaux, A., EORTC Radiotherapy Group, 2004. Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance. Report of the 22921 randomised trial conducted by the EORTC Radiotherapy Group. Eur. J. Cancer, 40(2):219–224. [doi:10.1016/j.ejca.2003.09.032]

    Article  CAS  PubMed  Google Scholar 

  • Cascino, I., Fiucci, G., Papoff, G., Ruberti, G., 1995. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J. Immunol., 154(6):2706–2713.

    CAS  PubMed  Google Scholar 

  • Chaudhry, P., Srinivasan, R., Patel, F.D., Gopalan, S., Majumdar, S., 2008. Serum soluble Fas levels and prediction of response to platinum-based chemotherapy in epithelial ovarian cancer. Int. J. Cancer, 122(8):1716–1721. [doi:10.1002/ijc.23213]

    Article  CAS  PubMed  Google Scholar 

  • Debatin, K.M., Krammer, P.H., 2004. Death receptors in chemotherapy and cancer. Oncogene, 23(16):2950–2966. [doi:10.1038/sj.onc.1207558]

    Article  CAS  PubMed  Google Scholar 

  • Eichhorst, S.T., Müerköster, S., Weigand, M.A., Krammer, P.H., 2001. The chemotherapeutic drug 5-fluorouracil induces apoptosis in mouse thymocytes in vivo via activation of the CD95 (APO-1/Fas) system. Cancer Res., 61(1):243–248.

    CAS  PubMed  Google Scholar 

  • Gratas, C., Tohma, Y., Barnas, C., Taniere, P., Hainaut, P., Ohgaki, H., 1998. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res., 58(10):2057–2062.

    CAS  PubMed  Google Scholar 

  • Griffith, T.S., Brunner, T., Fletcher, S.M., Green, D.R., Ferguson, T.A., 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science, 270(5239):1189–1192. [doi:10.1126/science.270.5239.1189]

    Article  CAS  PubMed  Google Scholar 

  • Havenga, K., Enker, W.E., Norstein, J., Moriya, Y., Heald, R.J., van Houwelingen, H.C., van de Velde, C.J., 1999. Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: an international analysis of 1411 patients. Eur. J. Surg. Oncol., 25(4):368–374. [doi:10.1053/ejso.1999.0659]

    Article  CAS  PubMed  Google Scholar 

  • Jodo, S., Kobayashi, S., Nakajima, Y., Matsunaga, T., Nakayama, N., Ogura, N., Kayagaki, N., Okumura, K., Koike, T., 1998. Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma. Clin. Exp. Immunol., 112(2):166–171. [doi:10.1046/j.1365-2249.1998.00569.x]

    Article  CAS  PubMed  Google Scholar 

  • Kachnic, L.A., 2007. Adjuvant chemoradiation for localized rectal cancer: current trends and future directions. Gastrointest. Cancer Res., 1(4 Suppl. 2):S64–S72.

    PubMed  Google Scholar 

  • Kimura, K., Gelmann, E.P., 2000. Tumor necrosis factor-alpha and Fas activate complementary Fas-associated death domain-dependent pathways that enhance apoptosis induced by gamma-irradiation. J. Biol. Chem., 275(12):8610–8617. [doi:10.1074/jbc.275.12.8610]

    Article  CAS  PubMed  Google Scholar 

  • Klautke, G., Feyerherd, P., Ludwig, K., Prall, F., Foitzik, T., Fietkau, R., 2005. Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer. Br. J. Cancer, 92(7):1215–1220. [doi:10.1038/sj.bjc.6602492]

    Article  CAS  PubMed  Google Scholar 

  • Kushlinskii, N.E., Britvin, T.A., Abbasova, S.G., Perevoshchikov, A.G., Prorokov, V.V., Kostanyan, I.A., Knysh, V.I., Lipkin, V.M., 2001. Soluble Fas antigen in the serum of patients with colon cancer. Bull. Exp. Biol. Med., 131(4):361–363. [doi:10.1023/A:1017908320634]

    Article  CAS  PubMed  Google Scholar 

  • Liang, Q.L., Pan, D.C., Yin, Z.M., Liu, G.X., Yang, Q., Xie, J.R., Cai, L.Z., Fu, Y.W., 2002. Clinical value of serum soluble Apo-1/Fas for predicting biological behaviors and prognosis of gastric carcinoma. Ai Zheng, 21(2):174–176 (in Chinese).

    PubMed  Google Scholar 

  • Liang, Q.L., Wang, B.R., Li, G.H., 2009. DcR3 and survivin are highly expressed in colorectal carcinoma and closely correlated to its clinicopathologic parameters. J. Zhejiang Univ.-Sci. B, 10(9):675–682. [doi:10.1631/jzus.B0920077]

    Article  CAS  PubMed  Google Scholar 

  • Natoli, G., Ianni, A., Costanzo, A., de Petrillo, G., Ilari, I., Chirillo, P., Balsano, C., Levrero, M., 1995. Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene, 11(6):1157–1164.

    CAS  PubMed  Google Scholar 

  • Naumnik, W., Izycki, T., Ossolinska, M., Chyczewska, E., 2007. Serum levels of sFas and sFasL during chemotherapy of lung cancer. Exp. Oncol., 29(2):132–136.

    CAS  PubMed  Google Scholar 

  • Nesbakken, A., Nygaard, K., Westerheim, O., Mala, T., Lunde, O.C., 2002. Local recurrence after mesorectal excision for rectal cancer. Eur. J. Surg. Oncol., 28(2):126–134. [doi:10.1053/ejso.2001.1231]

    Article  CAS  PubMed  Google Scholar 

  • Pan, G., Ahn, E.Y., Chen, Y., Feng, G., Reddy, V., Jhala, N.C., McDonald, J.M., 2007. Reciprocal co-expression of Fas and Fas ligand in human cholangiocarcinoma. Int. J. Oncol., 31(4):843–850.

    CAS  PubMed  Google Scholar 

  • Petak, I., Tillman, D.M., Harwood, F.G., Mihalik, R., Houghton, J.A., 2000. Fas-dependent and independent mechanisms of cell death following DNA damage in human colon carcinoma cells. Cancer Res., 60(10):2643–2650.

    CAS  PubMed  Google Scholar 

  • Shimizu, M., Kondo, M., Ito, Y., Kume, H., Suzuki, R., Yamaki, K., 2005. Soluble Fas and Fas ligand provide new information on metastasis and response to chemotherapy in SCLC patients. Cancer Detect. Prev., 29(2):175–180. [doi:10.1016/j.cdp.2004.09.001]

    Article  CAS  PubMed  Google Scholar 

  • Spindler, K.L., Nielsen, J.N., Lindebjerg, J., Brandslund, I., Jakobsen, A., 2006. Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region. Int. J. Radiat. Oncol. Biol. Phys., 66(2):500–504. [doi:10.1016/j.ijrobp.2006.03.030]

    Article  PubMed  CAS  Google Scholar 

  • Suda, T., Takahashi, T., Golstein, P., Nagata, S., 1993. Molecular cloning and expression of the Fas ligand a novel member of the tumor necrosis factor family. Cell, 75(6):1169–1178. [doi:10.1016/0092-8674(93)90326-L]

    Article  CAS  PubMed  Google Scholar 

  • Zhu, Q., Han, S.X., Li, M.Z., Su, B.S., Ma, J.L., 2006. The expression of Fas, p53, Bcl-2 and cervix carcinoma cell apoptosis during radiotherapy. Modern Oncol., 14(6):730–732 (in Chinese).

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center of Oncology, Affiliated Hospital of Guangdong Medical College, Zhanjiang, 524001, China

    Qi-lian Liang, Zhou-yu Li, Guo-qiang Chen, Zhen-nan Lai & Jie Huang

  2. Department of Chemotherapy, Affiliated Tumor Hospital of Guangzhou Medical College, Guangzhou, 510095, China

    Bi-rong Wang

Authors
  1. Qi-lian Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhou-yu Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guo-qiang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhen-nan Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bi-rong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jie Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Qi-lian Liang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liang, Ql., Li, Zy., Chen, Gq. et al. Prognostic value of serum soluble Fas in patients with locally advanced unresectable rectal cancer receiving concurrent chemoradiotherapy. J. Zhejiang Univ. Sci. B 11, 912–917 (2010). https://doi.org/10.1631/jzus.B1000277

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1631/jzus.B1000277

Key words

CLC number

Search

Navigation